This is probably why, in previous retrospective studies the high incidence of urothelial cancers in path_MSH2 carriers was not clearly described, the lower incidence of CRC in female than male path_MSH2 carriers probably was an artifact due to competing causes of death, and the later onset prostate cancers were also missed because of competing causes of death. The gene discussed is MSH2; the disease is prostate cancer.